title: Development of novel decoy oligonucleotides: advantages of circular dumb-bell decoy.
abstract: The inhibition of specific transcription regulatory proteins is a novel approach to regulate gene expression. The transcriptional activities of DNA binding proteins can be inhibited by the use of double-stranded oligonucleotides (ODNs) that compete for binding to their specific target sequences in promoters and enhancers. Transfection of this cis-element double-stranded ODN, referred to as decoy ODN, has been reported to be a powerful tool that provides a new class of anti-gene strategies to gene therapy and permits examination of specific gene regulation. We have demonstrated the usefulness of this decoy ODN strategy in animal models of restenosis, myocardial infarction, glomerulonephritis and rheumatoid arthritis. However, one of the major limitations of decoy ODN technology is the rapid degradation of phosphodiester ODNs by intracellular nucleases. To date, several different types of double-stranded decoy ODNs have been developed to overcome this issue. Circular dumb-bell (CD) double-stranded decoy ODNs that were developed to resolve this issue have attracted a high level of interest. In this review, the applications of decoy ODN strategy and the advantages of modified CD double-stranded decoy ODNs will be discussed.
authors.affiliation: Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka 565-0871, Japan. tomita@hp-gm.med.osaka-u.ac.jp
authors.forename: Naruya
authors.initials: N
authors.lastname: Tomita
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tomita
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yuyama
authors.forename: Takahiro
authors.initials: T
authors.lastname: Tougan
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Tajima
authors.forename: Toshio
authors.initials: T
authors.lastname: Ogihara
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Morishita
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D023903:Coronary Restenosis / Q000188:drug therapy*; D015316:Genetic Therapy; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D009841:Oligonucleotides / Q000627:therapeutic use*; D015534:Trans-Activators / Q000187:drug effects
chemical_list: D009841:Oligonucleotides; D015534:Trans-Activators